Terms: = Ovarian cancer AND JAK1, ENSG00000162434, P23458, JTK3, JAK1B, JAK1A, 3716 AND Treatment
10 results:
1. Multifactor assessment of ovarian cancer reveals immunologically interpretable molecular subtypes with distinct prognoses.
Guo Y; Li S; Li C; Wang L; Ning W
Front Immunol; 2023; 14():1326018. PubMed ID: 38143770
[TBL] [Abstract] [Full Text] [Related]
2. Mechanisms of carboplatin- and paclitaxel-dependent induction of premature senescence and pro-cancerogenic conversion of normal peritoneal mesothelium and fibroblasts.
Rutecki S; Pakuła-Iwańska M; Leśniewska-Bocianowska A; Matuszewska J; Rychlewski D; Uruski P; Stryczyński Ł; Naumowicz E; Szubert S; Tykarski A; Mikuła-Pietrasik J; Książek K
J Pathol; 2024 Feb; 262(2):198-211. PubMed ID: 37941520
[TBL] [Abstract] [Full Text] [Related]
3. Effects of Vitexin, a Natural Flavonoid Glycoside, on the Proliferation, Invasion, and Apoptosis of Human U251 Glioblastoma Cells.
Huang J; Zhou Y; Zhong X; Su F; Xu L
Oxid Med Cell Longev; 2022; 2022():3129155. PubMed ID: 35281458
[TBL] [Abstract] [Full Text] [Related]
4. IFNγ induces jak1/STAT1/p65 NFκB-dependent interleukin-8 expression in ovarian cancer cells, resulting in their increased migration.
Padmanabhan S; Gaire B; Zou Y; Uddin MM; DeLeon D; Vancurova I
Int J Biochem Cell Biol; 2021 Dec; 141():106093. PubMed ID: 34626802
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting.
Wu Z; Tao H; Zhang S; Wang X; Ma J; Li R; Liu Z; Wang J; Cui P; Chen S; Di H; Huang Z; Zheng X; Hu Y
Cancer Immunol Immunother; 2021 Oct; 70(10):2971-2980. PubMed ID: 33740125
[TBL] [Abstract] [Full Text] [Related]
6. Synthesis and biological evaluation of novel pyrazolo[1,5-a]pyrimidines: Discovery of a selective inhibitor of jak1 JH2 pseudokinase and VPS34.
Singleton JD; Dass R; Neubert NR; Smith RM; Webber Z; Hansen MDH; Peterson MA
Bioorg Med Chem Lett; 2020 Jan; 30(2):126813. PubMed ID: 31831383
[TBL] [Abstract] [Full Text] [Related]
7. Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer.
Liu S; Matsuzaki J; Wei L; Tsuji T; Battaglia S; Hu Q; Cortes E; Wong L; Yan L; Long M; Miliotto A; Bateman NW; Lele SB; Chodon T; Koya RC; Yao S; Zhu Q; Conrads TP; Wang J; Maxwell GL; Lugade AA; Odunsi K
J Immunother Cancer; 2019 Jun; 7(1):156. PubMed ID: 31221207
[TBL] [Abstract] [Full Text] [Related]
8. A comparison of two months pretreatment with GnRH agonists with or without an aromatase inhibitor in women with ultrasound-diagnosed ovarian endometriomas undergoing IVF.
Cantor A; Tannus S; Son WY; Tan SL; Dahan MH
Reprod Biomed Online; 2019 Apr; 38(4):520-527. PubMed ID: 30935663
[TBL] [Abstract] [Full Text] [Related]
9. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
[TBL] [Abstract] [Full Text] [Related]
10. The radiosensitivity of the human oocyte.
Wallace WH; Thomson AB; Kelsey TW
Hum Reprod; 2003 Jan; 18(1):117-21. PubMed ID: 12525451
[TBL] [Abstract] [Full Text] [Related]
